Production (Stage)
Crinetics Pharmaceuticals, Inc.
CRNX
$31.77
-$0.40-1.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.41% | -39.10% | -39.36% | -40.59% | -34.33% |
| Total Depreciation and Amortization | 151.05% | 153.64% | 102.42% | 61.50% | 25.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.55% | 48.46% | 67.47% | 72.92% | 60.43% |
| Change in Net Operating Assets | -105.20% | 44.64% | 858.98% | 492.09% | 167.96% |
| Cash from Operations | -46.58% | -35.88% | -22.58% | -11.36% | -25.33% |
| Capital Expenditure | 37.52% | 18.00% | 6.88% | -456.00% | -278.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -170.67% | -191.72% | -61.01% | -361.61% | -202.60% |
| Cash from Investing | -165.65% | -186.82% | -57.42% | -369.59% | -204.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.33% | 157.81% | 37.85% | 5,463.44% | 540.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 15.99% | -124.02% | 9.34% | -12,780.19% | -416.05% |
| Cash from Financing | -20.55% | 159.79% | 40.78% | 5,306.21% | 548.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.95% | 843.34% | 55.94% | 1,296.94% | 442.56% |